Evidence map›Paper›PMID 35899265›Full record

ArticleFrontiers in neurology2022

Case Report: Paraneoplastic Tumefactive Demyelination Associated With Seminoma.

Wataru Shiraishi, Takeru Umemura, Yuuki Nakayama, Yui Yamada, Masahiro Shijo, Tetsuya Hashimoto

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Post-COVID-19 Vaccination CNS Magnetic Resonance Imaging Findings: A Systematic Review.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Wataru ShiraishiDepartment of Neurology, Kokura Memorial Hospital, Kitakyushu, Japan.
Takeru UmemuraDepartment of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan.
Yuuki NakayamaDepartment of Urology, Kokura Memorial Hospital, Kitakyushu, Japan.
Yui YamadaDepartment of Pathology, Kokura Memorial Hospital, Kitakyushu, Japan.
Masahiro ShijoDepartment of Internal Medicine, Fukuoka Dental College Medical and Dental Hospital, Fukuoka, Japan.
Tetsuya HashimotoDepartment of Neurology, Kokura Memorial Hospital, Kitakyushu, Japan.
Kokura Memorial Hospital · JPFukuoka Dental College · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paraneoplastic tumefactive demyelination (TD) is a rare disorder of the central nervous system that can be challenging to diagnose. Here, we describe a 32-year-old Japanese man with a TD associated with testicular seminoma. He presented with symptoms of right-sided motor and sensory impairment 2 days after vaccination for coronavirus disease 2019 (COVID-19). Brain magnetic resonance imaging (MRI) showed a high-intensity lesion in the left internal capsule. He had a 3-year history of enlargement of the left testicle. Blood examination showed tumor marker elevation and the presence of anti-amphiphysin antibodies. Whole-body computed tomography (CT) revealed mass lesions in the left testicle and enlargement of the retroperitoneal lymph nodes. Radical orchiectomy was performed. As the pathology showed testicular seminoma, chemotherapy was administered. After surgery, his neurological symptoms deteriorated. MRI revealed that the brain lesion had enlarged and progressed to a tumefactive lesion without gadolinium enhancement. The cerebrospinal fluid (CSF) examination was normal without pleocytosis or protein elevation. Steroid pulse therapy was added; however, his symptoms did not improve. A brain stereotactic biopsy was performed and the sample showed demyelinating lesions without malignant cells. As the initial corticosteroid therapy was ineffective, gamma globulin therapy was administered in parallel with chemotherapy, and the clinical symptoms and imaging findings were partially ameliorated. TD seldom appears as a paraneoplastic neurological syndrome. In addition, there are few reports of COVID-19 vaccination-associated demyelinating disease. Clinicians should recognize paraneoplastic TD, and the further accumulation of similar cases is needed.

Indexed as

anti-amphiphysin antibodyCOVID-19 vaccinationdemyelinating diseaseparaneoplastic syndromeseminomastereotactic biopsysteroid therapytumefactive demyelination

Identifiers

PMID35899265
PMCPMC9309514
OpenAlexW4285005412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.